Total Payments
$399.68
2021 Payments
$87.06
Companies
7
Transactions
20
Medicare Patients
61,473
Medicare Billing
$6.8M
Payment Breakdown by Category
Food & Beverage$300.68 (75.2%)
Education$99.00 (24.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $300.68 | 19 | 75.2% |
| Education | $99.00 | 1 | 24.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $120.25 | 8 | $0 (2020) |
| Kite Pharma, Inc. | $102.63 | 6 | $0 (2021) |
| Amgen Inc. | $99.00 | 1 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $38.42 | 2 | $0 (2018) |
| Epizyme, Inc., | $14.74 | 1 | $0 (2021) |
| Spectrum Pharmaceuticals Inc. | $13.39 | 1 | $0 (2017) |
| Kyowa Kirin, Inc. | $11.25 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $87.06 | 5 | Kite Pharma, Inc. ($72.32) |
| 2020 | $41.99 | 3 | Kite Pharma, Inc. ($30.31) |
| 2019 | $42.32 | 3 | Novartis Pharmaceuticals Corporation ($31.07) |
| 2018 | $99.30 | 6 | Novartis Pharmaceuticals Corporation ($60.88) |
| 2017 | $129.01 | 3 | Amgen Inc. ($99.00) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $17.68 | General |
| 06/22/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $19.87 | General |
| 05/07/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $17.28 | General |
| 02/22/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $17.49 | General |
| 11/04/2020 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $11.68 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2020 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $14.54 | General |
| 08/31/2020 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $15.77 | General |
| 07/09/2019 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug), TASIGNA | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 02/20/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2019 | Kyowa Kirin, Inc. | SANCUSO (Drug), POTELIGEO | Food and Beverage | In-kind items and services | $11.25 | General |
| Category: ANTIEMETIC - 5HT3 INHIBITOR | ||||||
| 11/09/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/30/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/09/2018 | Novartis Pharmaceuticals Corporation | RECLAST (Drug) | Food and Beverage | In-kind items and services | $12.30 | General |
| Category: BONE | ||||||
| 02/26/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: HEMATOLOGY | ||||||
| 01/31/2018 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: ONCOLOGY | ||||||
| 01/09/2018 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: HEMATOLOGY | ||||||
| 10/31/2017 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: HEMATOLOGY | ||||||
| 10/25/2017 | Spectrum Pharmaceuticals Inc. | Zevalin (Drug) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: Not Applicable | ||||||
| 05/09/2017 | Amgen Inc. | — | Education | In-kind items and services | $99.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 87 | 14,016 | 122,785 | $6.1M | $1.1M |
| 2022 | 111 | 17,034 | 282,896 | $11.1M | $2.1M |
| 2021 | 98 | 16,851 | 304,028 | $12.2M | $2.2M |
| 2020 | 89 | 13,572 | 147,034 | $8.4M | $1.4M |
Total Patients
61,473
Total Services
856,743
Medicare Billing
$6.8M
Procedure Codes
385
All Medicare Procedures & Services
385 procedure records from CMS Medicare Utilization — Page 1 of 16
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 567 | 1,491 | $684,810 | $171,016 | 25.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 365 | 827 | $777,380 | $134,401 | 17.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 31 | 4,980 | $455,400 | $90,229 | 19.8% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 144 | 3,425 | $369,576 | $80,133 | 21.7% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 286 | 1,454 | $218,100 | $80,113 | 36.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 42 | 48,000 | $240,000 | $41,720 | 17.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 18 | 15,800 | $316,000 | $36,682 | 11.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 747 | 2,454 | $147,240 | $25,263 | 17.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 859 | 2,961 | $59,220 | $24,723 | 41.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 825 | 2,979 | $446,850 | $22,564 | 5.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 600 | 1,454 | $218,100 | $19,272 | 8.8% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 304 | 1,989 | $89,505 | $18,099 | 20.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 52 | 135 | $74,250 | $17,342 | 23.4% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 264 | 970 | $67,900 | $16,383 | 24.1% |
| 83735 | Magnesium level | Office | 2023 | 684 | 2,247 | $168,525 | $14,676 | 8.7% |
| 82306 | Vitamin d-3 level | Office | 2023 | 324 | 466 | $69,900 | $13,410 | 19.2% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 13 | 38 | $79,800 | $13,152 | 16.5% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 490 | 889 | $66,675 | $13,099 | 19.6% |
| 86334 | Immunologic analysis technique on serum (immunofixation) | Office | 2023 | 292 | 598 | $65,780 | $13,068 | 19.9% |
| 88184 | Flow cytometry technique for dna or cell analysis, first marker | Office | 2023 | 145 | 178 | $53,400 | $12,946 | 24.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 63 | 63 | $49,140 | $12,654 | 25.8% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 426 | 735 | $110,250 | $12,066 | 10.9% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 663 | 1,980 | $59,400 | $11,680 | 19.7% |
| 82746 | Folic acid level, serum | Office | 2023 | 470 | 814 | $56,980 | $11,661 | 20.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 71 | 103 | $39,140 | $11,335 | 29.0% |
About Dr. Gurmohan Syali, MD
Dr. Gurmohan Syali, MD is a Medical Oncology healthcare provider based in E Setauket, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1932195138.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gurmohan Syali, MD has received a total of $399.68 in payments from pharmaceutical and medical device companies, with $87.06 received in 2021. These payments were reported across 20 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($300.68).
As a Medicare-enrolled provider, Syali has provided services to 61,473 Medicare beneficiaries, totaling 856,743 services with total Medicare billing of $6.8M. Data is available for 4 years (2020–2023), covering 385 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location E Setauket, NY
- Active Since 09/22/2005
- Last Updated 03/24/2014
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1932195138
Products in Payments
- XARELTO (Drug) $38.42
- RYDAPT (Drug) $36.13
- KISQALI (Drug) $30.64
- JADENU (Drug) $16.16
- TAZVERIK (Drug) $14.74
- Zevalin (Drug) $13.39
- PROMACTA (Drug) $13.34
- RECLAST (Drug) $12.30
- PIQRAY (Drug) $11.68
- SANCUSO (Drug) $11.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.